Comparable exposure in literature was reported following administration of conventional nonbiologic UC and CD medications metabolized via CYP3A between patients with UC or CD and healthy subjects (or patients with inactive IBD or in remission). The gene discussed is CYP3A4; the disease is inflammatory bowel disease.